Home This healthtech start-up that delivers more accurate drug doses has raised a $2.6m Series A round at a $20m valuation DoseMe founder Dr Robert McLeay, Steve Baxter, DoseMe CEO Charles Cornish and DoseMe Series A investor Greg Spurgin
DoseMe founder Dr Robert McLeay, Steve Baxter, DoseMe CEO Charles Cornish and DoseMe Series A investor Greg Spurgin
